Notice of Clarification of NCATS Research Priorities for PA-14-307 "Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)"

Notice Number: NOT-TR-16-008

Key Dates
Release Date: January 22, 2016  

Related Announcements
PA-14-307    

Issued by
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to modify NCATS research interests in PA-14-307 "Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)".

Part 2. Section I.  Funding Opportunity Description

Background

Currently reads:  It is important to note however that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more common conditions such as infectious diseases, cancer, and addictive disorders.

Modified to Read:  It is important to note, however, that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more common conditions such as infectious diseases, cancer, and addictive disorders.  However, for new submissions, NCATS will give priority to technologies directed to the treatment of diseases other than cancer.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Philip J. Brooks, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-443-0513
Email:  pjbrooks@mail.nih.gov